<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/72"/><api:result><api:object category="publication" id="72" last-affected-when="2024-04-13T19:19:47.24+01:00" last-modified-when="2024-04-13T19:19:47.24+01:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/72" created-when="2010-05-17T13:46:10.517+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-02-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1387379" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1097/00007691-199902000-00010" last-modified-when="2022-09-10T09:00:30.75+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>van Lent-Evers</api:last-name><api:initials>NAEM</api:initials><api:first-names>Nicolette AEM</api:first-names><api:separate-first-names><api:first-name>Nicolette</api:first-name><api:first-name>A</api:first-name><api:first-name>E</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mathôt</api:last-name><api:initials>RAA</api:initials><api:first-names>Ron AA</api:first-names><api:separate-first-names><api:first-name>Ron</api:first-name><api:first-name>A</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Geus</api:last-name><api:initials>WP</api:initials><api:first-names>William P</api:first-names><api:separate-first-names><api:first-name>William</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>Ben A</api:first-names><api:separate-first-names><api:first-name>Ben</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinks</api:last-name><api:initials>AATMM</api:initials><api:first-names>Alexander ATMM</api:first-names><api:separate-first-names><api:first-name>Alexander</api:first-name><api:first-name>A</api:first-name><api:first-name>T</api:first-name><api:first-name>M</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00007691-199902000-00010</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00007691-199902000-00010"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00007691-199902000-00010"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0163-4356</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Therapeutic Drug Monitoring</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>63</api:begin-page><api:end-page>73</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Ovid Technologies (Wolters Kluwer Health)</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1097/00007691-199902000-00010</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>16</api:day><api:month>6</api:month><api:year>2021</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Impact of Goal-Oriented and Model-Based Clinical Pharmacokinetic Dosing of Aminoglycosides on Clinical Outcome: A Cost-Effectiveness Analysis</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>21</api:text></api:field></api:native></api:record><api:record format="native" id="131488" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0033024908" last-modified-when="2024-03-27T15:48:01.32+00:00"><api:citation-count>216</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The benefits of a pharmacy-based, active therapeutic drug monitoring (TDM) service (ATM) on outcomes were examined in a prospective study at four hospitals. ATM involved pharmacokinetic dosage optimization at the start of treatment, subsequent Bayesian adaptive control, and frequent patient evaluation. Costeffectiveness was calculated based on real costs. The ATM group comprised 105 patients and 127 patients with nonguided TDM who were followed up as controls. Forty-eight of the ATM and 62 of the nonguided TDM patients had an infection on admission. Peak concentrations in ATM patients were significantly higher (10.6 ± 2.9 mg/L; nonguided TDM, 7.6 ± 2.2 mg/L; p &lt; 0.01). Trough levels in the ATM group were significantly lower (p &lt; 0.01). There was a trend toward lower mortality in the ATM group (nine of 105 versus 18 of 127; p = 0.26) that was significant for patients with an infection on admission (one of the 48 ATM patients died versus nine of the 62 nonguided TDM patients; p = 0.023). ATM reduced the length of hospital stay for all patients in the study (20.0 ± 1.4 days; nonguided TDM, 26.3 ± 2.9 days; p = 0.045) and for patients admitted with an infection (12.6 ± 0.8 days; nonguided TDM, 18.0 ± 1.4; p &lt; 0.001). The incidence of nephrotoxicity was reduced from 13.4% (nonguided TDM) to 2.9% (p &lt; 0.01). With ATM, total costs were lower for all patients (Dutch guilders [DFL], 13,125 ± 9,267; nonguided TDM, DFL 16,862 ± 17,721; p &lt; 0.05) and for patients admitted with an infection (DFL 8,883 ± 3,778; nonguided TDM, DFL 11,743 ± 7,437; p &lt; 0.01). Goal-oriented, model-based dosing of aminoglycosides resulted in higher antibiotic efficacy, shorter hospitalization, and reduced incidence of nephrotoxicity. By combining efficacy with savings, ATM offered a significant alternative to usual care.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Van Lent-Evers</api:last-name><api:initials>NAEM</api:initials><api:first-names>NAEM</api:first-names><api:separate-first-names><api:first-name>N</api:first-name><api:first-name>A</api:first-name><api:first-name>E</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Hague Central Hospital Pharmacy</api:line><api:line type="city">Leiden</api:line><api:line type="country">Netherlands</api:line></api:address><api:address iso-country-code="NL"><api:line type="organisation">Lorentz Hospital Zeist</api:line><api:line type="city">Zeist</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">37050178800</api:identifier></api:identifiers></api:person><api:person><api:last-name>Mathôt</api:last-name><api:initials>RAA</api:initials><api:first-names>RAA</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>A</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Hague Central Hospital Pharmacy</api:line><api:line type="city">Leiden</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7004492604</api:identifier></api:identifiers></api:person><api:person><api:last-name>Geus</api:last-name><api:initials>WP</api:initials><api:first-names>WP</api:first-names><api:separate-first-names><api:first-name>W</api:first-name><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Leids Universitair Medisch Centrum</api:line><api:line type="city">Leiden</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6603891377</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>Van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Erasmus Universiteit Rotterdam</api:line><api:line type="city">Rotterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57191081993</api:identifier></api:identifiers></api:person><api:person><api:last-name>Vinks</api:last-name><api:initials>AATMM</api:initials><api:first-names>AATMM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>A</api:first-name><api:first-name>T</api:first-name><api:first-name>M</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Hague Central Hospital Pharmacy</api:line><api:line type="city">Leiden</api:line><api:line type="country">Netherlands</api:line></api:address><api:address iso-country-code="NL"><api:line type="organisation">Central Hospital Pharmacy</api:line><api:line type="city">Den Haag</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7003656582</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00007691-199902000-00010</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00007691-199902000-00010"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00007691-199902000-00010"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10051056</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0163-4356</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Therapeutic Drug Monitoring</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>63</api:begin-page><api:end-page>73</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>21</api:text></api:field></api:native></api:record><api:record format="native" id="72" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10051056" last-modified-when="2020-04-29T01:30:54.37+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The benefits of a pharmacy-based, active therapeutic drug monitoring (TDM) service (ATM) on outcomes were examined in a prospective study at four hospitals. ATM involved pharmacokinetic dosage optimization at the start of treatment, subsequent Bayesian adaptive control, and frequent patient evaluation. Cost-effectiveness was calculated based on real costs. The ATM group comprised 105 patients and 127 patients with nonguided TDM who were followed up as controls. Forty-eight of the ATM and 62 of the nonguided TDM patients had an infection on admission. Peak concentrations in ATM patients were significantly higher (10.6+/-2.9 mg/L; nonguided TDM, 7.6+/-2.2 mg/L; p &lt; 0.01). Trough levels in the ATM group were significantly lower (p &lt; 0.01). There was a trend toward lower mortality in the ATM group (nine of 105 versus 18 of 127; p = 0.26) that was significant for patients with an infection on admission (one of the 48 ATM patients died versus nine of the 62 nonguided TDM patients; p = 0.023). ATM reduced the length of hospital stay for all patients in the study (20.0+/-1.4 days; nonguided TDM, 26.3+/-2.9 days; p = 0.045) and for patients admitted with an infection (12.6+/-0.8 days; nonguided TDM, 18.0+/-1.4; p &lt; 0.001). The incidence of nephrotoxicity was reduced from 13.4% (nonguided TDM) to 2.9% (p &lt; 0.01). With ATM, total costs were lower for all patients (Dutch guilders [DFL], 13,125+/-9,267; nonguided TDM, DFL 16,862+/-17,721; p &lt; 0.05) and for patients admitted with an infection (DFL 8,883+/-3,778; nonguided TDM, DFL 11,743+/-7,437; p &lt; 0.01). Goal-oriented, model-based dosing of aminoglycosides resulted in higher antibiotic efficacy, shorter hospitalization, and reduced incidence of nephrotoxicity. By combining efficacy with savings, ATM offered a significant alternative to usual care.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>van Lent-Evers</api:last-name><api:initials>NA</api:initials><api:first-names>NA</api:first-names><api:separate-first-names><api:first-name>N</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="full">TDM and Clinical Toxicology Laboratory, The Hague Central Hospital Pharmacy, The Netherlands.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Mathôt</api:last-name><api:initials>RA</api:initials><api:first-names>RA</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Geus</api:last-name><api:initials>WP</api:initials><api:first-names>WP</api:first-names><api:separate-first-names><api:first-name>W</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinks</api:last-name><api:initials>AA</api:initials><api:first-names>AA</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10051056</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00007691-199902000-00010</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00007691-199902000-00010"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00007691-199902000-00010"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0163-4356</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Ther Drug Monit</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aminoglycosides</api:keyword><api:keyword scheme="mesh">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Drug Monitoring</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Gram-Negative Bacterial Infections</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Length of Stay</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Outcome Assessment, Health Care</api:keyword><api:keyword scheme="mesh">Prospective Studies</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>United States</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>63</api:begin-page><api:end-page>73</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>28</api:day><api:month>5</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Comparative Study</api:item><api:item>Journal Article</api:item><api:item>Multicenter Study</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>21</api:text></api:field></api:native></api:record><api:record format="native" id="872995" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10051056" last-modified-when="2024-02-14T00:48:57.71+00:00"><api:citation-count>110</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The benefits of a pharmacy-based, active therapeutic drug monitoring (TDM) service (ATM) on outcomes were examined in a prospective study at four hospitals. ATM involved pharmacokinetic dosage optimization at the start of treatment, subsequent Bayesian adaptive control, and frequent patient evaluation. Cost-effectiveness was calculated based on real costs. The ATM group comprised 105 patients and 127 patients with nonguided TDM who were followed up as controls. Forty-eight of the ATM and 62 of the nonguided TDM patients had an infection on admission. Peak concentrations in ATM patients were significantly higher (10.6+/-2.9 mg/L; nonguided TDM, 7.6+/-2.2 mg/L; p &lt; 0.01). Trough levels in the ATM group were significantly lower (p &lt; 0.01). There was a trend toward lower mortality in the ATM group (nine of 105 versus 18 of 127; p = 0.26) that was significant for patients with an infection on admission (one of the 48 ATM patients died versus nine of the 62 nonguided TDM patients; p = 0.023). ATM reduced the length of hospital stay for all patients in the study (20.0+/-1.4 days; nonguided TDM, 26.3+/-2.9 days; p = 0.045) and for patients admitted with an infection (12.6+/-0.8 days; nonguided TDM, 18.0+/-1.4; p &lt; 0.001). The incidence of nephrotoxicity was reduced from 13.4% (nonguided TDM) to 2.9% (p &lt; 0.01). With ATM, total costs were lower for all patients (Dutch guilders [DFL], 13,125+/-9,267; nonguided TDM, DFL 16,862+/-17,721; p &lt; 0.05) and for patients admitted with an infection (DFL 8,883+/-3,778; nonguided TDM, DFL 11,743+/-7,437; p &lt; 0.01). Goal-oriented, model-based dosing of aminoglycosides resulted in higher antibiotic efficacy, shorter hospitalization, and reduced incidence of nephrotoxicity. By combining efficacy with savings, ATM offered a significant alternative to usual care.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="NL"><api:line type="full">TDM and Clinical Toxicology Laboratory, The Hague Central Hospital Pharmacy, The Netherlands.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>van Lent-Evers</api:last-name><api:initials>NA</api:initials><api:first-names>NA</api:first-names><api:separate-first-names><api:first-name>N</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mathôt</api:last-name><api:initials>RA</api:initials><api:first-names>RA</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Geus</api:last-name><api:initials>WP</api:initials><api:first-names>WP</api:first-names><api:separate-first-names><api:first-name>W</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinks</api:last-name><api:initials>AA</api:initials><api:first-names>AA</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0003-4224-2967</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00007691-199902000-00010</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00007691-199902000-00010"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00007691-199902000-00010"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1536-3694</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10051056</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0163-4356</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Therapeutic drug monitoring</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Gram-Negative Bacterial Infections</api:keyword><api:keyword scheme="mesh">Aminoglycosides</api:keyword><api:keyword scheme="mesh">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh">Drug Monitoring</api:keyword><api:keyword scheme="mesh">Length of Stay</api:keyword><api:keyword scheme="mesh">Prospective Studies</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Outcome Assessment, Health Care</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>63</api:begin-page><api:end-page>73</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>2</api:day><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Comparative Study</api:item><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Multicenter Study</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>21</api:text></api:field></api:native></api:record><api:record format="native" id="2739626" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1060274643" last-modified-when="2024-04-13T19:19:47.247+01:00"><api:citation-count>207</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>van Lent-Evers</api:last-name><api:initials>NAEM</api:initials><api:first-names>Nicolette AEM</api:first-names><api:separate-first-names><api:first-name>Nicolette</api:first-name><api:first-name>A</api:first-name><api:first-name>E</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="full">*TDM and Clinical Toxicology Laboratory, The Hague Central Hospital Pharmacy, The Hague, †Department of Intensive Care, Leyenburg Hospital, The Hague, Department of Gastroenterology, Leiden University Medical Center, Leiden, and the ‡Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Mathôt</api:last-name><api:initials>RAA</api:initials><api:first-names>Ron AA</api:first-names><api:separate-first-names><api:first-name>Ron</api:first-name><api:first-name>A</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="full">*TDM and Clinical Toxicology Laboratory, The Hague Central Hospital Pharmacy, The Hague, †Department of Intensive Care, Leyenburg Hospital, The Hague, Department of Gastroenterology, Leiden University Medical Center, Leiden, and the ‡Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.015365777517.05</api:identifier></api:identifiers></api:person><api:person><api:last-name>Geus</api:last-name><api:initials>WP</api:initials><api:first-names>William P</api:first-names><api:separate-first-names><api:first-name>William</api:first-name><api:first-name>P</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="full">*TDM and Clinical Toxicology Laboratory, The Hague Central Hospital Pharmacy, The Hague, †Department of Intensive Care, Leyenburg Hospital, The Hague, Department of Gastroenterology, Leiden University Medical Center, Leiden, and the ‡Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.014465345754.24</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>Ben A</api:first-names><api:separate-first-names><api:first-name>Ben</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="full">*TDM and Clinical Toxicology Laboratory, The Hague Central Hospital Pharmacy, The Hague, †Department of Intensive Care, Leyenburg Hospital, The Hague, Department of Gastroenterology, Leiden University Medical Center, Leiden, and the ‡Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01167771713.07</api:identifier></api:identifiers></api:person><api:person><api:last-name>Vinks</api:last-name><api:initials>AATMM</api:initials><api:first-names>Alexander ATMM</api:first-names><api:separate-first-names><api:first-name>Alexander</api:first-name><api:first-name>A</api:first-name><api:first-name>T</api:first-name><api:first-name>M</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="full">*TDM and Clinical Toxicology Laboratory, The Hague Central Hospital Pharmacy, The Hague, †Department of Intensive Care, Leyenburg Hospital, The Hague, Department of Gastroenterology, Leiden University Medical Center, Leiden, and the ‡Institute for Medical Technology Assessment (iMTA), Erasmus University, Rotterdam, The Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01160662243.81</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00007691-199902000-00010</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00007691-199902000-00010"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00007691-199902000-00010"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10051056</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0163-4356</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Therapeutic Drug Monitoring</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="rcdc">Comparative Effectiveness Research</api:keyword><api:keyword scheme="rcdc">Cost Effectiveness Research</api:keyword><api:keyword scheme="rcdc">Orphan Drug</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Rare Diseases</api:keyword><api:keyword scheme="sdg">3 Good Health and Well Being</api:keyword><api:keyword scheme="mesh">Aged</api:keyword><api:keyword scheme="mesh">Aminoglycosides</api:keyword><api:keyword scheme="mesh">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Drug Monitoring</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Gram-Negative Bacterial Infections</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Length of Stay</api:keyword><api:keyword scheme="mesh">Male</api:keyword><api:keyword scheme="mesh">Outcome Assessment, Health Care</api:keyword><api:keyword scheme="mesh">Prospective Studies</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>63</api:begin-page><api:end-page>73</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Wolters Kluwer</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>5.02</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Impact of Goal-Oriented and Model-Based Clinical Pharmacokinetic Dosing of Aminoglycosides on Clinical Outcome: A Cost-Effectiveness Analysis</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>21</api:text></api:field></api:native></api:record><api:record format="native" id="239697" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000078486600009" last-modified-when="2024-03-27T20:44:06.31+00:00"><api:citation-count>173</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>van Lent-Evers</api:last-name><api:initials>NAEM</api:initials><api:first-names>NAEM</api:first-names><api:separate-first-names><api:first-name>N</api:first-name><api:first-name>A</api:first-name><api:first-name>E</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mathôt</api:last-name><api:initials>RAA</api:initials><api:first-names>RAA</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>A</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Geus</api:last-name><api:initials>WP</api:initials><api:first-names>WP</api:first-names><api:separate-first-names><api:first-name>W</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinks</api:last-name><api:initials>AATMM</api:initials><api:first-names>AATMM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>A</api:first-name><api:first-name>T</api:first-name><api:first-name>M</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000078486600009&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00007691-199902000-00010</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00007691-199902000-00010"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00007691-199902000-00010"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1536-3694</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">164WM</api:identifier><api:identifier scheme="pubmed">10051056</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0163-4356</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>THERAPEUTIC DRUG MONITORING</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>aminoglycosides</api:keyword><api:keyword>cost-effectiveness</api:keyword><api:keyword>clinical outcome</api:keyword><api:keyword>therapeutic drug monitoring</api:keyword><api:keyword>gentamicin</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>63</api:begin-page><api:end-page>73</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome:: A cost-effectiveness analysis</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>21</api:text></api:field></api:native></api:record><api:record format="native" id="22195" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000078486600009" last-modified-when="2014-07-25T11:00:29.35+01:00"><api:citation-count>40</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>van Lent-Evers</api:last-name><api:initials>NAEM</api:initials><api:first-names>NAEM</api:first-names><api:separate-first-names><api:first-name>N</api:first-name><api:first-name>A</api:first-name><api:first-name>E</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Mathot</api:last-name><api:initials>RAA</api:initials><api:first-names>RAA</api:first-names><api:separate-first-names><api:first-name>R</api:first-name><api:first-name>A</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Geus</api:last-name><api:initials>WP</api:initials><api:first-names>WP</api:first-names><api:separate-first-names><api:first-name>W</api:first-name><api:first-name>P</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Vinks</api:last-name><api:initials>AATMM</api:initials><api:first-names>AATMM</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>A</api:first-name><api:first-name>T</api:first-name><api:first-name>M</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0163-4356</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>1</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>THER DRUG MONIT</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>aminoglycosides</api:keyword><api:keyword>cost-effectiveness</api:keyword><api:keyword>clinical outcome</api:keyword><api:keyword>therapeutic drug monitoring</api:keyword><api:keyword>gentamicin</api:keyword><api:keyword>BENEFIT-ANALYSIS</api:keyword><api:keyword>DOSAGE REGIMENS</api:keyword><api:keyword>BURN PATIENTS</api:keyword><api:keyword>PLASMA-LEVELS</api:keyword><api:keyword>GENTAMICIN</api:keyword><api:keyword>HOSPITALIZATION</api:keyword><api:keyword>NEPHROTOXICITY</api:keyword><api:keyword>ASSOCIATION</api:keyword><api:keyword>SERVICE</api:keyword><api:keyword>TRIAL</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>63</api:begin-page><api:end-page>73</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>2</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>21</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Aminoglycosides</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Drug Monitoring</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Gram-Negative Bacterial Infections</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Length of Stay</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Outcome Assessment, Health Care</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Prospective Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Gram-Negative Bacterial Infections</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aminoglycosides</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Drug Monitoring</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Length of Stay</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Prospective Studies</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Outcome Assessment, Health Care</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Comparative Effectiveness Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cost Effectiveness Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Orphan Drug</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Rare Diseases</api:keyword><api:keyword scheme="sdg" origin="record-data" source="dimensions">3 Good Health and Well Being</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aged</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Aminoglycosides</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Anti-Bacterial Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Drug Monitoring</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Gram-Negative Bacterial Infections</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Length of Stay</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Male</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Outcome Assessment, Health Care</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Prospective Studies</api:keyword><api:keyword origin="record-data" source="wos-lite">aminoglycosides</api:keyword><api:keyword origin="record-data" source="wos-lite">cost-effectiveness</api:keyword><api:keyword origin="record-data" source="wos-lite">clinical outcome</api:keyword><api:keyword origin="record-data" source="wos-lite">therapeutic drug monitoring</api:keyword><api:keyword origin="record-data" source="wos-lite">gentamicin</api:keyword><api:keyword origin="record-data" source="wos">aminoglycosides</api:keyword><api:keyword origin="record-data" source="wos">cost-effectiveness</api:keyword><api:keyword origin="record-data" source="wos">clinical outcome</api:keyword><api:keyword origin="record-data" source="wos">therapeutic drug monitoring</api:keyword><api:keyword origin="record-data" source="wos">gentamicin</api:keyword><api:keyword origin="record-data" source="wos">BENEFIT-ANALYSIS</api:keyword><api:keyword origin="record-data" source="wos">DOSAGE REGIMENS</api:keyword><api:keyword origin="record-data" source="wos">BURN PATIENTS</api:keyword><api:keyword origin="record-data" source="wos">PLASMA-LEVELS</api:keyword><api:keyword origin="record-data" source="wos">GENTAMICIN</api:keyword><api:keyword origin="record-data" source="wos">HOSPITALIZATION</api:keyword><api:keyword origin="record-data" source="wos">NEPHROTOXICITY</api:keyword><api:keyword origin="record-data" source="wos">ASSOCIATION</api:keyword><api:keyword origin="record-data" source="wos">SERVICE</api:keyword><api:keyword origin="record-data" source="wos">TRIAL</api:keyword><api:keyword scheme="for" origin="issn-inferred">0301 Analytical Chemistry</api:keyword><api:keyword scheme="for" origin="issn-inferred">1115 Pharmacology and Pharmaceutical Sciences</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Pharmacology &amp; Pharmacy</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3214 Pharmacology and pharmaceutical sciences</api:keyword></api:keywords></api:all-labels><api:journal issn="0163-4356" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973058" title="Therapeutic Drug Monitoring"><api:records><api:record source-name="summary"><api:title>Therapeutic Drug Monitoring</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/72/relationships"/></api:object></api:result></api:response>